AR094452A1 - COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O INFa - Google Patents
COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O INFaInfo
- Publication number
- AR094452A1 AR094452A1 ARP130104091A ARP130104091A AR094452A1 AR 094452 A1 AR094452 A1 AR 094452A1 AR P130104091 A ARP130104091 A AR P130104091A AR P130104091 A ARP130104091 A AR P130104091A AR 094452 A1 AR094452 A1 AR 094452A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- alkyl
- heteroatoms selected
- carbon atoms
- case
- Prior art date
Links
- 241000670727 Amida Species 0.000 title 1
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 11
- 239000001257 hydrogen Substances 0.000 abstract 11
- 125000005842 heteroatom Chemical group 0.000 abstract 10
- 229910052760 oxygen Inorganic materials 0.000 abstract 10
- 229910052717 sulfur Inorganic materials 0.000 abstract 10
- 125000000623 heterocyclic group Chemical group 0.000 abstract 9
- 150000002431 hydrogen Chemical class 0.000 abstract 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 125000004432 carbon atom Chemical group C* 0.000 abstract 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 3
- 101150105130 RORB gene Proteins 0.000 abstract 3
- 229910052794 bromium Inorganic materials 0.000 abstract 3
- 229910052801 chlorine Inorganic materials 0.000 abstract 3
- 229910052731 fluorine Inorganic materials 0.000 abstract 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 abstract 2
- 108010081348 HRT1 protein Hairy Proteins 0.000 abstract 2
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 229910052805 deuterium Inorganic materials 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723840P | 2012-11-08 | 2012-11-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR094452A1 true AR094452A1 (es) | 2015-08-05 |
Family
ID=49876960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130104091A AR094452A1 (es) | 2012-11-08 | 2013-11-07 | COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O INFa |
Country Status (39)
Families Citing this family (114)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2015005561A (es) | 2012-11-08 | 2015-07-23 | Squibb Bristol Myers Co | Compuestos de pirimidina sustituidos con alquil-amida utiles en la modulacion de interleucina 12 (il-12) interleucina 23 (il-23) y/o interferon alfa (ifn alfa). |
| UY35126A (es) * | 2012-11-08 | 2014-05-30 | Bristol Myers Squibb Co | Ojo es alfa |
| AR094537A1 (es) | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa |
| CN105992768B (zh) | 2013-12-10 | 2018-04-20 | 百时美施贵宝公司 | 用作IL‑12、IL‑23和/或IFNα响应的调节剂的咪唑并哒嗪化合物 |
| WO2015123453A1 (en) * | 2014-02-14 | 2015-08-20 | Portola Pharmaceuticals, Inc. | Pyridazine compounds as jak inhibitors |
| KR102097878B1 (ko) * | 2015-11-26 | 2020-04-06 | 노파르티스 아게 | 디아미노 피리딘 유도체 |
| TWI825663B (zh) | 2016-10-14 | 2023-12-11 | 美商林伯士拉克許米公司 | Tyk2抑制劑及其用途 |
| EP3528816A4 (en) | 2016-10-21 | 2020-04-08 | Nimbus Lakshmi, Inc. | TYK2 INHIBITORS AND USES THEREOF |
| MA48602A (fr) * | 2016-12-13 | 2020-03-18 | Bristol Myers Squibb Co | Composés hétéroaryle substitués par un amide alkyle d'oxyde de phosphine en tant que modulateurs des réponses il-12, il-23 et/ou ifn alpha |
| JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
| US10336752B2 (en) | 2017-03-08 | 2019-07-02 | Nimbus Lakshmi, Inc. | TYK2 inhibitors, uses, and methods for production thereof |
| IL305615A (en) * | 2017-03-30 | 2023-11-01 | Bristol Myers Squibb Co | Crystal form of -6(cyclopropanecarboxamido)-4-((-2methoxy-3-(-1methyl- 4 2, 1-1,H-triazol-3-yl)phenyl(amino)-N-)methyl-D3(pyridazine -3-carboxamide |
| JP7258903B2 (ja) * | 2017-11-21 | 2023-04-17 | ブリストル－マイヤーズ スクイブ カンパニー | スルホンピリジンアルキルアミド置換ヘテロアリール化合物 |
| AR117398A1 (es) | 2018-03-12 | 2021-08-04 | Abbvie Inc | Inhibidores de la señalización mediada por tirosina cinasa 2 |
| CN111936486B (zh) * | 2018-03-22 | 2023-09-22 | 百时美施贵宝公司 | 用作IL-12、IL-23和/或IFNα响应的调节剂的包含吡啶的杂环化合物 |
| CN118994117A (zh) * | 2018-05-31 | 2024-11-22 | 百时美施贵宝公司 | 化合物的结晶形式 |
| TWI898556B (zh) | 2018-07-13 | 2025-09-21 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒衍生物 |
| GB201816369D0 (en) | 2018-10-08 | 2018-11-28 | Sareum Ltd | Pharmaceutical compounds |
| CN113271940A (zh) | 2018-10-15 | 2021-08-17 | 林伯士拉克许米公司 | Tyk2抑制剂和其用途 |
| JP7631193B2 (ja) | 2018-10-22 | 2025-02-18 | アルミス インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用 |
| US12240840B2 (en) * | 2018-10-30 | 2025-03-04 | Bristol-Myers Squibb Company | Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha |
| CN113271938A (zh) | 2018-11-30 | 2021-08-17 | 林伯士拉克许米公司 | Tyk2抑制剂和其用途 |
| WO2020154474A1 (en) | 2019-01-23 | 2020-07-30 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| WO2020156311A1 (zh) * | 2019-01-28 | 2020-08-06 | 江苏豪森药业集团有限公司 | 一种哒嗪类衍生物抑制剂、其制备方法和应用 |
| CN111484480B (zh) * | 2019-01-29 | 2023-08-11 | 上海翰森生物医药科技有限公司 | 一种多环类衍生物抑制剂、其制备方法和应用 |
| SG11202108162SA (en) * | 2019-01-30 | 2021-08-30 | Bristol Myers Squibb Co | Amide-disubstituted pyridine or pyridazine compounds |
| US11357775B2 (en) | 2019-04-30 | 2022-06-14 | Celgene Corporation | Combination therapies comprising apremilast and Tyk2 inhibitors |
| MX2021013317A (es) * | 2019-04-30 | 2022-01-18 | Celgene Corp | Terapias de combinacion que comprenden inhibidores de apremilast y tyk2. |
| CN120309591A (zh) * | 2019-06-12 | 2025-07-15 | 百时美施贵宝公司 | 化合物的结晶盐形式 |
| WO2021011513A1 (en) | 2019-07-16 | 2021-01-21 | Bristol-Myers Squibb Company | Prodrugs in the modulation of interleukin |
| EP4007757B1 (en) | 2019-08-01 | 2025-09-10 | Sperogenix Therapeutics Limited | Heterocyclic compounds as kinase inhibitor and uses thereof |
| EP4027995A4 (en) | 2019-09-13 | 2023-08-23 | Nimbus Saturn, Inc. | HPK1 ANTAGONISTS AND THEIR APPLICATIONS |
| US20230255964A1 (en) | 2019-09-18 | 2023-08-17 | Bristol-Myers Squibb Company | Extended release dosage forms for tyk2 inhibitors |
| US20230039086A1 (en) * | 2019-12-17 | 2023-02-09 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Bms-986165 crystal form, preparation method therefor and use thereof |
| WO2021143498A1 (zh) * | 2020-01-19 | 2021-07-22 | 苏州科睿思制药有限公司 | 一种Deucravacitinib的晶型及其制备方法和用途 |
| WO2021143430A1 (zh) * | 2020-01-19 | 2021-07-22 | 苏州科睿思制药有限公司 | 一种bms-986165盐酸盐晶型及其制备方法和用途 |
| CN115003667B (zh) * | 2020-02-26 | 2025-04-15 | 百济神州有限公司 | Tyk-2抑制剂 |
| MX2022011297A (es) | 2020-03-11 | 2022-10-07 | Beijing Innocare Pharma Tech Co Ltd | Compuestos heterociclicos para inhibir las actividades de tyk2. |
| WO2021204626A1 (en) * | 2020-04-06 | 2021-10-14 | Almirall, S.A. | Aryl and heteroaryl-carboxamide substituted heteroaryl compounds as tyk2 inhibitors |
| GB202005114D0 (en) | 2020-04-07 | 2020-05-20 | Sareum Ltd | Crystalline Forms of a Pharmaceutical Compound |
| CN113563309B (zh) * | 2020-04-28 | 2024-12-13 | 浙江海正药业股份有限公司 | 吡啶类衍生物及其制备方法和用途 |
| KR20230004771A (ko) * | 2020-04-28 | 2023-01-06 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn알파 조정제로서의 치환된 n-(메틸-d3)피리다진-3-카르복스아미드 또는 n-(메틸-d3)-니코틴아미드 화합물 |
| CN113735836B (zh) * | 2020-05-28 | 2023-05-30 | 江苏先声药业有限公司 | 哒嗪类化合物及其应用 |
| CN113735837B (zh) * | 2020-05-28 | 2023-09-01 | 江苏先声药业有限公司 | 哒嗪类化合物及其用途 |
| CN113773262B (zh) * | 2020-06-09 | 2024-08-09 | 江苏先声药业有限公司 | 哒嗪类化合物 |
| IL299294A (en) | 2020-06-22 | 2023-02-01 | Beigene Ltd | tyk-2 inhibitor |
| CN113968846A (zh) * | 2020-07-24 | 2022-01-25 | 上海翰森生物医药科技有限公司 | 一种哒嗪类衍生物的盐、晶型及其制备方法和应用 |
| CA3186000A1 (en) * | 2020-07-24 | 2022-01-27 | Shanghai Hansoh Biomedical Co., Ltd. | Crystal form of pyridazine derivative free base, and preparation method therefor and use thereof |
| EP3944859A1 (en) | 2020-07-30 | 2022-02-02 | Assistance Publique Hôpitaux de Paris | Method for treating immune toxicities induced by immune checkpoint inhibitors |
| CN114057651B (zh) * | 2020-07-31 | 2025-05-27 | 正大天晴药业集团股份有限公司 | 含酰胺基的tyk2抑制剂化合物 |
| WO2022021684A1 (zh) * | 2020-07-31 | 2022-02-03 | 苏州科睿思制药有限公司 | 一种bms-986165盐酸盐晶型csv及其制备方法和用途 |
| US20240325388A1 (en) * | 2020-09-18 | 2024-10-03 | Bristol-Myers Squibb Company | Dosage forms for tyk2 inhibitors comprising swellable cores |
| CN116615200B (zh) * | 2020-10-20 | 2025-04-29 | 杭州领业医药科技有限公司 | 哒嗪衍生物的晶型 |
| EP4232425A4 (en) | 2020-10-23 | 2024-07-24 | Nimbus Clotho, Inc. | Ctps1 inhibitors and uses thereof |
| CN120887875A (zh) * | 2020-11-12 | 2025-11-04 | 上海睿跃生物科技有限公司 | 酪氨酸激酶2(tyk2)降解化合物和使用方法 |
| TW202227430A (zh) * | 2020-11-17 | 2022-07-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 含氮雜環類衍生物、其製備方法及其在醫藥上的應用 |
| CN116547276A (zh) * | 2020-12-08 | 2023-08-04 | 正大天晴药业集团股份有限公司 | 含酰胺基和杂环烷基的tyk2抑制剂化合物 |
| JP2024505063A (ja) * | 2021-01-29 | 2024-02-02 | ブリストル－マイヤーズ スクイブ カンパニー | ６－（シクロプロパンカルボキサミド）－４－（（２－メトキシ－３－（１－メチル－１Ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－Ｎ－（メチル－ｄ３）ピリダジン－３－カルボキサミドの結晶形態 |
| AU2022215844A1 (en) | 2021-02-02 | 2023-09-14 | Liminal Biosciences Limited | Gpr84 antagonists and uses thereof |
| CN117098757A (zh) | 2021-02-02 | 2023-11-21 | 里米诺生物科学有限公司 | Gpr84拮抗剂和其用途 |
| TW202233600A (zh) * | 2021-02-06 | 2022-09-01 | 大陸商正大天晴藥業集團股份有限公司 | 含聯環的ｔｙｋ２抑制劑化合物、藥物組合物及其用途 |
| CN114907326B (zh) * | 2021-02-06 | 2025-02-18 | 正大天晴药业集团股份有限公司 | 含酰胺基和联环的tyk2抑制剂化合物 |
| CN117120090A (zh) | 2021-02-12 | 2023-11-24 | 林伯士萨顿公司 | Hpk1拮抗剂和其用途 |
| AU2022222470A1 (en) | 2021-02-19 | 2023-09-21 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| WO2022175752A1 (en) | 2021-02-19 | 2022-08-25 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| US11926625B2 (en) | 2021-03-05 | 2024-03-12 | Nimbus Saturn, Inc. | HPK1 antagonists and uses thereof |
| JP2024510274A (ja) * | 2021-03-16 | 2024-03-06 | アンルイ バイオメディカル テクノロジー （グァンヂョウ） カンパニー リミテッド | アミノヘテロアリール化合物および組成物 |
| WO2022212181A1 (en) | 2021-03-29 | 2022-10-06 | Bristol-Myers Squibb Company | Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide |
| EP4313989A4 (en) | 2021-03-29 | 2025-03-05 | Nimbus Saturn, Inc. | HPK1 ANTAGONISTS AND USES THEREOF |
| US20240182429A1 (en) * | 2021-03-30 | 2024-06-06 | Zhejiang Wenda Pharma Technology Ltd. | Heterocyclic compound as tyk2 pseudokinase domain inhibitor, synthetic method, and use |
| CN115197196B (zh) * | 2021-04-06 | 2024-06-18 | 扬子江药业集团有限公司 | Tyk2抑制剂及其用途 |
| EP4319756A4 (en) | 2021-04-09 | 2025-02-26 | Nimbus Clio, Inc. | CBL-B MODULATORS AND USES THEREOF |
| EP4335440A4 (en) * | 2021-05-04 | 2025-05-14 | Shanghai Zheye Biotechnology Co., Ltd. | NITROGEN-CONTAINING HETEROCYCLIC PYRIDINE COMPOUND |
| US20240317718A1 (en) * | 2021-05-14 | 2024-09-26 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
| TW202311247A (zh) * | 2021-05-14 | 2023-03-16 | 美商必治妥美雅史谷比公司 | 經取代之雜環化合物 |
| US20250066322A1 (en) | 2021-05-14 | 2025-02-27 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
| US20240270723A1 (en) | 2021-05-14 | 2024-08-15 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
| WO2022253335A1 (zh) * | 2021-06-02 | 2022-12-08 | 南京明德新药研发有限公司 | 含磺酰基的芳基类化合物及其应用 |
| CN115466289A (zh) * | 2021-06-11 | 2022-12-13 | 爱科诺生物医药(香港)有限公司 | 具有tyk2抑制活性的化合物，包含其的药物组合物，及其应用 |
| BR112023026964A2 (pt) * | 2021-06-22 | 2024-03-12 | Medshine Discovery Inc | Composto de sulfoximina e uso do mesmo |
| CN117794911A (zh) * | 2021-07-15 | 2024-03-29 | 南京明德新药研发有限公司 | 含硫/磷的芳基类化合物及其应用 |
| WO2023023322A1 (en) * | 2021-08-20 | 2023-02-23 | Bristol-Myers Squibb Company | Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide |
| WO2023027948A1 (en) * | 2021-08-21 | 2023-03-02 | Relay Therapeutics, Inc. | Jak2 inhibitors and methods of use thereof |
| EP4404930A1 (en) | 2021-09-23 | 2024-07-31 | Bristol-Myers Squibb Company | Methods of treating hair-loss disorders with tyk2 inhibitors |
| JP2024535467A (ja) | 2021-09-30 | 2024-09-30 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔｙｋ２阻害剤に対する応答性を決定する方法 |
| CN119013277A (zh) | 2021-10-25 | 2024-11-22 | 凯麦拉医疗公司 | Tyk2降解剂和其用途 |
| EP4422690A1 (en) | 2021-10-28 | 2024-09-04 | Bristol-Myers Squibb Company | Topical formulations of deucravacitinib |
| EP4441043A1 (en) | 2021-12-01 | 2024-10-09 | Teva Czech Industries s.r.o | Solid state forms of deucravacitinib, deucravacitinib hcl and process for preparation of deucravacitinib and intermediates |
| WO2023108536A1 (en) * | 2021-12-16 | 2023-06-22 | Lynk Pharmaceuticals Co. Ltd. | Tyk2 inhibitors and compositions and methods thereof |
| TW202339749A (zh) * | 2021-12-16 | 2023-10-16 | 大陸商凌科藥業有限公司 | Ｔｙｋ２抑制劑及其組合物和方法 |
| CN116283928A (zh) * | 2021-12-20 | 2023-06-23 | 艾立康药业股份有限公司 | 一种哒嗪类化合物、其制备方法和应用 |
| EP4206196A1 (en) | 2021-12-29 | 2023-07-05 | Almirall S.A. | Pyrimidine substituted derivatives as tyk2 inhibitors |
| CN116693449A (zh) | 2022-03-04 | 2023-09-05 | 上海致根医药科技有限公司 | 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用 |
| CN119233971A (zh) * | 2022-05-31 | 2024-12-31 | 上海华汇拓医药科技有限公司 | 一种哒嗪类化合物、其制备方法和用途 |
| WO2024020221A1 (en) | 2022-07-21 | 2024-01-25 | Arvinas Operations, Inc. | Modulators of tyk2 proteolysis and associated methods of use |
| WO2024028364A1 (en) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Limited | Aryl-triazolyl and related gpr84 antagonists and uses thereof |
| IL318576A (en) | 2022-08-02 | 2025-03-01 | Liminal Biosciences Ltd | Pyridoxine-substituted GPR84 antagonists and their uses |
| KR20250057800A (ko) | 2022-08-02 | 2025-04-29 | 리미널 바이오사이언시스 리미티드 | 헤테로아릴 카복스아마이드 및 관련 gpr84 길항제 및 이의 용도 |
| EP4615832A1 (en) | 2022-11-08 | 2025-09-17 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
| WO2024127363A1 (en) | 2022-12-16 | 2024-06-20 | Alembic Pharmaceuticals Limited | Tyk2 pseudokinase ligands and uses thereof |
| CN116284040B (zh) * | 2023-01-05 | 2024-05-28 | 华润医药研究院（深圳）有限公司 | 含氮杂环类化合物及其医药用途 |
| CN120693328A (zh) * | 2023-02-07 | 2025-09-23 | 浙江华海药业股份有限公司 | 一种哒嗪类化合物、其制备方法和用途 |
| CN118724752B (zh) * | 2023-03-29 | 2025-11-28 | 重庆博腾制药科技股份有限公司 | 一种酪氨酸激酶抑制剂中间体、制备方法及其应用 |
| CN116162093B (zh) * | 2023-04-25 | 2023-06-23 | 中南大学湘雅医院 | 一种tyk2抑制剂化合物及其用途 |
| WO2024236491A1 (en) * | 2023-05-15 | 2024-11-21 | Glenmark Life Sciences Limited | Process for the preparation of deucravacitinib, and crystalline forms thereof |
| CN119080742A (zh) * | 2023-06-05 | 2024-12-06 | 甘莱制药有限公司 | 脂质合成的杂环调节剂的工业化制备 |
| WO2024257023A1 (en) | 2023-06-14 | 2024-12-19 | Alembic Pharmaceuticals Limited | Tyk2 pseudokinase ligands and uses thereof |
| TW202529769A (zh) | 2023-09-21 | 2025-08-01 | 日商武田藥品工業股份有限公司 | Ｔｙｋ２抑制劑及其用途 |
| CN117447353A (zh) * | 2023-09-21 | 2024-01-26 | 爱斯特（成都）生物制药股份有限公司 | 一种氘可来昔替尼中间体的制备方法 |
| EP4538259A1 (en) | 2023-10-09 | 2025-04-16 | Farmhispania Group, S.L. | Processes for the preparation of deucravacitinib |
| WO2025131031A1 (zh) * | 2023-12-22 | 2025-06-26 | 上海奥博生物医药股份有限公司 | 一种TyK2抑制剂及其中间体的制备方法 |
| WO2025186427A1 (en) | 2024-03-08 | 2025-09-12 | Curia Spain, S.A.U. | Process for the preparation of deucravacitinib and intermediates thereof and method for purifying deucravacitinib |
| CN118593504B (zh) * | 2024-06-03 | 2025-03-18 | 北京大学第三医院（北京大学第三临床医学院） | 氘可来昔替尼或其盐在制备pvns药物方面的新用途 |
| CN119059972B (zh) * | 2024-08-12 | 2025-10-28 | 武汉九州钰民医药科技有限公司 | 一种btk抑制剂吡托布鲁替尼的合成方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1184376B1 (en) * | 1999-06-09 | 2005-02-02 | Yamanouchi Pharmaceutical Co. Ltd. | Novel heterocyclic carboxamide derivatives |
| JP4622047B2 (ja) * | 1999-06-09 | 2011-02-02 | アステラス製薬株式会社 | 新規なヘテロ環カルボキサミド誘導体 |
| AU5108000A (en) * | 1999-06-10 | 2001-01-02 | Yamanouchi Pharmaceutical Co., Ltd. | Novel nitrogen-contaiing heterocyclic derivatives or salts thereof |
| US7273868B2 (en) | 2000-04-28 | 2007-09-25 | Tanabe Seiyaku Co., Ltd. | Pyrazine derivatives |
| CA2356544C (en) | 2000-10-03 | 2006-04-04 | Warner-Lambert Company | Pyridotriazines and pyridopyridazines |
| MXPA05000655A (es) | 2002-07-15 | 2006-02-22 | Harvard College | Metodos y composiciones para modular el desarrollo y la funcion de las celulas t helper (th). |
| US7176214B2 (en) | 2003-05-21 | 2007-02-13 | Bristol-Myers Squibb Company | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
| WO2011113802A2 (en) | 2010-03-17 | 2011-09-22 | F. Hoffmann-La Roche Ag | Imidazopyridine compounds, compositions and methods of use |
| BR112013006016A2 (pt) | 2010-09-15 | 2016-06-07 | Hoffmann La Roche | compostos de azabenzotiazol, composições e métodos de uso |
| KR20140009259A (ko) | 2010-11-19 | 2014-01-22 | 에프. 호프만-라 로슈 아게 | 피라졸로피리딘 및 tyk2 억제제로서 이의 용도 |
| JP5878178B2 (ja) * | 2011-09-30 | 2016-03-08 | 大鵬薬品工業株式会社 | １，２，４−トリアジン−６−カルボキサミド誘導体 |
| WO2013104573A1 (en) * | 2012-01-10 | 2013-07-18 | F. Hoffmann-La Roche Ag | Pyridazine amide compounds and their use as syk inhibitors |
| UY34807A (es) * | 2012-05-16 | 2013-12-31 | Novartis Ag | Derivados monocíclicos de heteroarilcicloalquil- diamina |
| US9040530B2 (en) | 2012-06-22 | 2015-05-26 | Portola Pharmaceuticals, Inc. | 1,2,4-triazine-6-carboxamide kinase inhibitors |
| HK1211024A1 (en) | 2012-10-19 | 2016-05-13 | 霍夫曼-拉罗奇有限公司 | Inhibitors of syk |
| BR112015010244A8 (pt) | 2012-11-08 | 2019-10-01 | Bristol Myers Squibb Co | compostos de piridila substituída por alquil-amida úteis como moduladores de il-12, il-23 e/ou respostas de ifnalfa, sua composição farmacêutica e seu uso |
| MX2015005561A (es) | 2012-11-08 | 2015-07-23 | Squibb Bristol Myers Co | Compuestos de pirimidina sustituidos con alquil-amida utiles en la modulacion de interleucina 12 (il-12) interleucina 23 (il-23) y/o interferon alfa (ifn alfa). |
| UY35126A (es) * | 2012-11-08 | 2014-05-30 | Bristol Myers Squibb Co | Ojo es alfa |
| AR094537A1 (es) | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa |
| IL305615A (en) | 2017-03-30 | 2023-11-01 | Bristol Myers Squibb Co | Crystal form of -6(cyclopropanecarboxamido)-4-((-2methoxy-3-(-1methyl- 4 2, 1-1,H-triazol-3-yl)phenyl(amino)-N-)methyl-D3(pyridazine -3-carboxamide |
-
2013
- 2013-11-07 UY UY0001035126A patent/UY35126A/es unknown
- 2013-11-07 SI SI201331986T patent/SI3495358T1/sl unknown
- 2013-11-07 PL PL13811640T patent/PL2922846T3/pl unknown
- 2013-11-07 SG SG10201706897TA patent/SG10201706897TA/en unknown
- 2013-11-07 HU HUE13811640A patent/HUE041750T2/hu unknown
- 2013-11-07 LT LTEP13811640.5T patent/LT2922846T/lt unknown
- 2013-11-07 TW TW102140572A patent/TWI605041B/zh active
- 2013-11-07 US US14/441,183 patent/US9505748B2/en not_active Ceased
- 2013-11-07 MY MYPI2022004735A patent/MY198262A/en unknown
- 2013-11-07 HR HRP20220766TT patent/HRP20220766T1/hr unknown
- 2013-11-07 MY MYPI2015701475A patent/MY175448A/en unknown
- 2013-11-07 MX MX2015005731A patent/MX2015005731A/es active IP Right Grant
- 2013-11-07 EA EA201590917A patent/EA028814B1/ru not_active IP Right Cessation
- 2013-11-07 KR KR1020157014694A patent/KR102195194B1/ko active Active
- 2013-11-07 DK DK13811640.5T patent/DK2922846T3/en active
- 2013-11-07 CN CN201380069692.9A patent/CN104884454B/zh active Active
- 2013-11-07 BR BR112015010102-0A patent/BR112015010102B1/pt active IP Right Grant
- 2013-11-07 RS RS20220589A patent/RS63328B1/sr unknown
- 2013-11-07 LT LTEP18197550.9T patent/LT3495358T/lt unknown
- 2013-11-07 EP EP13811640.5A patent/EP2922846B1/en active Active
- 2013-11-07 PL PL18197550T patent/PL3495358T3/pl unknown
- 2013-11-07 AU AU2013341186A patent/AU2013341186B2/en active Active
- 2013-11-07 DK DK18197550.9T patent/DK3495358T3/da active
- 2013-11-07 SG SG11201503399XA patent/SG11201503399XA/en unknown
- 2013-11-07 PT PT13811640T patent/PT2922846T/pt unknown
- 2013-11-07 SM SM20190001T patent/SMT201900001T1/it unknown
- 2013-11-07 EP EP22165094.8A patent/EP4071144A1/en active Pending
- 2013-11-07 WO PCT/US2013/068846 patent/WO2014074661A1/en not_active Ceased
- 2013-11-07 TR TR2018/20824T patent/TR201820824T4/tr unknown
- 2013-11-07 ES ES18197550T patent/ES2914793T3/es active Active
- 2013-11-07 HU HUE18197550A patent/HUE059409T2/hu unknown
- 2013-11-07 CA CA2890981A patent/CA2890981C/en active Active
- 2013-11-07 SM SM20220258T patent/SMT202200258T1/it unknown
- 2013-11-07 PT PT181975509T patent/PT3495358T/pt unknown
- 2013-11-07 US US16/201,653 patent/USRE47929E1/en active Active
- 2013-11-07 EP EP18197550.9A patent/EP3495358B8/en active Active
- 2013-11-07 MY MYPI2020005025A patent/MY194668A/en unknown
- 2013-11-07 PE PE2015000607A patent/PE20150944A1/es active IP Right Grant
- 2013-11-07 HR HRP20181937TT patent/HRP20181937T1/hr unknown
- 2013-11-07 JP JP2015541883A patent/JP6407159B2/ja active Active
- 2013-11-07 NZ NZ708859A patent/NZ708859A/en unknown
- 2013-11-07 MA MA38072A patent/MA38072A1/fr unknown
- 2013-11-07 RS RS20181428A patent/RS58187B1/sr unknown
- 2013-11-07 AR ARP130104091A patent/AR094452A1/es active IP Right Grant
- 2013-11-07 SG SG10201706985UA patent/SG10201706985UA/en unknown
- 2013-11-07 SI SI201331219T patent/SI2922846T1/sl unknown
- 2013-11-07 ES ES13811640T patent/ES2702148T3/es active Active
-
2015
- 2015-05-04 IL IL238610A patent/IL238610A0/en active IP Right Grant
- 2015-05-06 PH PH12015501004A patent/PH12015501004A1/en unknown
- 2015-05-06 MX MX2020003156A patent/MX2020003156A/es unknown
- 2015-05-07 CL CL2015001231A patent/CL2015001231A1/es unknown
- 2015-06-05 ZA ZA2015/04052A patent/ZA201504052B/en unknown
-
2016
- 2016-10-10 US US15/289,437 patent/US10000480B2/en active Active
-
2017
- 2017-02-17 AU AU2017201076A patent/AU2017201076B2/en active Active
-
2018
- 2018-05-15 US US15/979,770 patent/US10526321B2/en active Active
- 2018-05-16 JP JP2018094837A patent/JP6585231B2/ja active Active
- 2018-11-19 AU AU2018267545A patent/AU2018267545B2/en active Active
- 2018-12-14 CY CY20181101343T patent/CY1121188T1/el unknown
-
2019
- 2019-09-04 JP JP2019161215A patent/JP2020002157A/ja active Pending
- 2019-11-18 US US16/687,279 patent/US11021475B2/en active Active
-
2020
- 2020-06-15 AU AU2020203967A patent/AU2020203967B2/en active Active
-
2021
- 2021-04-29 US US17/244,938 patent/US20220356180A1/en not_active Abandoned
-
2022
- 2022-06-02 CY CY20221100391T patent/CY1125220T1/el unknown
-
2023
- 2023-07-24 NL NL301238C patent/NL301238I2/nl unknown
- 2023-07-27 CY CY2023017C patent/CY2023017I2/el unknown
- 2023-08-10 HU HUS2300025C patent/HUS2300025I1/hu unknown
- 2023-08-14 FR FR23C1030C patent/FR23C1030I2/fr active Active
- 2023-08-23 LT LTPA2023523C patent/LTC2922846I2/lt unknown
- 2023-08-25 NO NO2023032C patent/NO2023032I1/no unknown
- 2023-08-28 FI FIC20230028C patent/FIC20230028I1/fi unknown
-
2024
- 2024-09-10 US US18/830,387 patent/US20250243193A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR094452A1 (es) | COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O INFa | |
| AR094537A1 (es) | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa | |
| AR093403A1 (es) | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA UTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL23 Y/O INFa | |
| AR113895A1 (es) | Compuestos de heteroarilo sustituidos con alquilamida de piridinsulfona | |
| AR129635A2 (es) | Moduladores de tetrahidropiridopirazina de gpr6 | |
| AR062928A1 (es) | Inhibidores de la actividad quinasa utiles en el tratamiento de trastornos mediados por mecanismos de ikk2 | |
| AR090867A1 (es) | Compuestos y composiciones plaguicidas y procesos relacionados | |
| AR088534A1 (es) | Composiciones plaguicidas y procesos relacionados con dichas composiciones | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR089865A1 (es) | Derivados de bencimidazol e imidazopiridinas como moduladores de canales de sodio | |
| AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR085410A1 (es) | Derivados de pirazol heteroaril-sustituidos, composiciones pesticidas que los comprenden y su uso en el control de plagas | |
| AR090045A1 (es) | Compuestos de isotiazolina para combatir plagas de invertebrados | |
| AR095422A1 (es) | Compuestos de piperidina sustituidos y su uso como moduladores de receptores de orexina | |
| AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
| AR092270A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR107170A1 (es) | Compuestos heterocíclicos tricíclicos condesados como inhibidores de integrasa del vih | |
| AR094496A1 (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
| AR104555A1 (es) | SULFONAS TRICÍCLICAS COMO MODULARES DE RORg | |
| ECSP11010901A (es) | Compuestos de amida útiles en terapia | |
| AR089814A1 (es) | Compuestos que modulan la actividad de los proteasomas | |
| AR093782A1 (es) | Uso de compuestos de antranilamida para reducir infecciones virales cuyo vector es un insecto | |
| AR112794A1 (es) | Compuestos heteroaromáticos sustituidos con cicloolefinas y su uso en el tratamiento de enfermedades inducidas por mutaciones idh |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |